09:01 AM EDT, 09/18/2024 (MT Newswires) -- Sonnet BioTherapeutics Holdings ( SONN ) said Wednesday it has completed patient enrollment and begun dosing in the phase 1 trial of its investigational cancer therapy, SON-1010, for advanced solid tumors.

The company said it expects to report topline results in Q4.

The study, which involves 24 adult patients, is an open-label trial assessing the safety, tolerability, and pharmacokinetics of SON-1010 and is expected to help determine the maximum tolerated dose, Sonnet said.

Shares of the company were up 1.2% in recent Wednesday premarket activity.

Price: 0.9628, Change: +0.01, Percent Change: +1.24